

NOW ENROLLING IN UROTHELIAL CANCER



PHASE 2 (NCT03785925)

PIVOT-10: Bempegaldesleukin with nivolumab in patients with advanced urothelial cancer

A single-arm study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) in cisplatin-ineligible, locally advanced or metastatic urothelial cancer¹

ENROLL NOW

Scan here to find out more about this clinical study at ClinicalTrials.gov



POPULATION

- Untreated metastatic or unresectable urothelial cancer
- Ineligible for cisplatin
- Any PD-L1 status

N_≈205



BEMPEG + NIVO

PRIMARY ENDPOINT

- ORR (in PD-L1-low tumors)

SECONDARY ENDPOINTS

- ORR and DOR
- Safety and tolerability

Bempegaldesleukin is an investigational first-in-class CD122-preferential IL-2-pathway agonist²

Nivolumab is a PD-1 blocking antibody³

BEMPEG, bempegaldesleukin (NKTR-214); DOR, duration of response; IL-2, interleukin-2; NIVO, nivolumab; ORR, objective response rate; PD-1, programmed death-1; PD-L1, programmed death-ligand 1.

1. [ClinicalTrials.gov. NCT03785925. https://clinicaltrials.gov/ct2/show/NCT03785925](https://clinicaltrials.gov/ct2/show/NCT03785925). Accessed May 1, 2020. 2. Charych DH, et al. *Clin Cancer Res* 2016;22:680-690. 3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: May 2020).


CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB ARE NOW ENROLLING

NEKTAR

 Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverage two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE
Scan here to discover more about BEMPEG at Nektar.com



BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab.

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2020. All rights reserved.